Table 1 Patient characteristics.
From: SREBP1 site 1 protease inhibitor PF-429242 suppresses renal cell carcinoma cell growth
Patient No. | Type | R/L | Gender | Age | Ki-67% | Stage |
|---|---|---|---|---|---|---|
Patient-1 | ccRCC | R | F | 62 | 30% | IV |
Patient-2 | ccRCC | R | M | 41 | 20% | III |
Patient-3 | ccRCC | R | M | 49 | 1% | II |
Patient-4 | ccRCC | L | M | 70 | 1% | III |
Patient-5 | ccRCC | R | M | 56 | 5% | II |
Patient-6 | ccRCC | R | M | 67 | 10% | III |
Patient-7 | ccRCC | R | F | 82 | 10% | II |
Patient-8 | ccRCC | R | M | 69 | 3% | III |
